Janux Therapeutics, Inc. (JANX)
NASDAQ:JANX
Want to see JANX full AI Analyst Report?
JANX Stock Chart & Stats
$15.82
-$2.71(-4.69%)
At close: 4:00 PM EST
$15.82
-$2.71(-4.69%)
Day’s Range― - ―
52-Week Range$12.12 - $35.34
Previous CloseN/A
Volume1.13M
Average Volume (3M)898.96K
Market Cap
$833.05M
Enterprise Value$859.50M
Total Cash (Recent Filing)$956.39M
Total Debt (Recent Filing)$21.57M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Aug 11, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding60,984,352
10 Day Avg. Volume737,260
30 Day Avg. Volume898,957
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)0.89
Price to Sales (P/S)85.51
P/FCF Ratio-10.27
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue39.77
Enterprise Value/Gross Profit73.44
Enterprise Value/Ebitda-7.64
Forecast
1Y Price Target
$31.42Price Target Upside98.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-1.77
Revenue Forecast (FY)$29.49M
Bulls Say, Bears Say
Bulls Say
Platform Differentiation (TRACTr)The TRACTr platform’s differentiated tolerability and ability to dose beyond conventional T cell engagers provides a durable competitive advantage: it can enable broader outpatient dosing, larger therapeutic windows across targets, and improve probability of delivering clinically meaningful results across multiple programs.
Low Financial LeverageVery low leverage gives Janux material financial flexibility to fund clinical programs and prioritize R&D without immediate debt pressures. This balance-sheet strength reduces near-term refinancing risk and supports execution through typical biotech development cycles over the next several months.
Advancing Pipeline And Revenue ReboundContinued clinical starts and program advancement, together with a TTM revenue rebound, indicate active pipeline progression and early commercial/partnering inflows. Sustained clinical momentum and improving top-line trends enhance optionality for partnerships, milestone receipts, and long-term program value realization.
Bears Say
High Cash Burn / Weak Cash GenerationPersistently negative operating and free cash flow mean the company must rely on external financing or collaborations to fund development. Continued burn without stabilization increases dilution risk and could force reprioritization of programs, constraining long-term execution and optionality.
Deep, Persistent LossesSubstantial operating losses and negative margins erode shareholder capital and limit internal funding capacity for trials. Over time, persistent unprofitability increases dependence on external capital, raising execution and strategic risk for advancing multiple late preclinical and clinical programs.
Program Discontinuation Indicates Execution RiskTerminating JANX008 reduces pipeline breadth and highlights the inherent clinical and target-specific risks of oncology programs. While learnings may inform the platform, program failures can delay timelines, reallocate resources, and limit near-term catalysts necessary for durable value creation.
Janux Therapeutics Inc News
JANX FAQ
What was Janux Therapeutics, Inc.’s price range in the past 12 months?
Janux Therapeutics, Inc. lowest stock price was $12.12 and its highest was $35.34 in the past 12 months.
What is Janux Therapeutics, Inc.’s market cap?
Janux Therapeutics, Inc.’s market cap is $833.05M.
When is Janux Therapeutics, Inc.’s upcoming earnings report date?
Janux Therapeutics, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 60 days.
How were Janux Therapeutics, Inc.’s earnings last quarter?
Janux Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.551 by $0.161.
Is Janux Therapeutics, Inc. overvalued?
According to Wall Street analysts Janux Therapeutics, Inc.’s price is currently Undervalued.
Does Janux Therapeutics, Inc. pay dividends?
Janux Therapeutics, Inc. does not currently pay dividends.
What is Janux Therapeutics, Inc.’s EPS estimate?
Janux Therapeutics, Inc.’s EPS estimate is -0.27.
How many shares outstanding does Janux Therapeutics, Inc. have?
Janux Therapeutics, Inc. has 60,984,352 shares outstanding.
What happened to Janux Therapeutics, Inc.’s price movement after its last earnings report?
Janux Therapeutics, Inc. reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.551. Following the earnings report the stock price went down -2.51%.
Which hedge fund is a major shareholder of Janux Therapeutics, Inc.?
Currently, no hedge funds are holding shares in JANX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Janux Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.42 (98.59% Upside)
$31.42 (98.59% Upside)
Blogger Sentiment
Bullish
JANX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 289.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $85.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.34%
12-Months-Change
Fundamentals
Return on Equity
-11.85%
Trailing 12-Months
Asset Growth
-2.15%
Trailing 12-Months
Company Description
Janux Therapeutics, Inc.
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
JANX Stock 12 Month Forecast
Average Price Target
$31.42
▲(98.59% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Vera Therapeutics
―
Biohaven Ltd.
―
Ownership Overview
19.65% Insiders
14.21% Mutual Funds
44.93% Other Institutional Investors
10.04% Public Companies and
Individual Investors